VAV3 mediates resistance to breast cancer endocrine therapy

Breast Cancer Research

Volumn 16, Issue 3, 2014, Pages

  Aguilar, Helena ^a   Urruticoechea, Ander ^a,v   Halonen, Pasi ^b   Kiyotani, Kazuma ^c   Mushiroda, Taisei ^c   Barril, Xavier ^d,e   Serra Musach, Jordi ^a,f   Islam, Abul ^g   Caizzi, Livia ^h,i   Di Croce, Luciano ^e,h,i   Nevedomskaya, Ekaterina ^b   Zwart, Wilbert ^b   Bostner, Josefine ^j   Karlsson, Elin ^j   Pérez Tenorio, Gizeh ^j   Fornander, Tommy ^k   Sgroi, Dennis C ^l   Garcia Mata, Rafael ^m   Jansen, Maurice P H M ⁿ   García, Nadia ^o   Bonifaci, Núria ^a   Climent, Fina ^p   Soler, María T ^p   Rodríguez Vida, Alejo ^o   Gil, Miguel ^o   Brunet, Joan ^f   Martrat, Griselda ^a   Gómez Baldó, Laia ^a   Extremera, Ana I ^a   Figueras, Agnes ^o   Balart, Josep ^o   Clarke, Robert ^q   Burnstein, Kerry L ^r   Carlson, Kathryn E ^s   Katzenellenbogen, John A ^s   Vizoso, Miguel ^a   Esteller, Manel ^a,d,e   Villanueva, Alberto ^o   Rodríguez Peña, Ana B ^t   Bustelo, Xosé R ^t   Nakamura, Yusuke ^c,u   Zembutsu, Hitoshi ^u   Stål, Olle ^j   Beijersbergen, Roderick L ^b   Pujana, Miguel A ^a   more..

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RIKEN   (Japan)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^g UNIVERSITY OF DHAKA   (Bangladesh)

^h CENTRE FOR GENOMIC REGULATION CRG   (Spain)

ⁱ UNIVERSITAT POMPEU FABRA   (Spain)

^j LINKÖPING UNIVERSITY   (Sweden)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ ERASMUS MC CANCER INSTITUTE   (Netherlands)

^o ICO   (Spain)

^p HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^q GEORGETOWN UNIVERSITY   (United States)

^r UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^s UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^t CSIC   (Spain)

^u UNIVERSITY OF TOKYO   (Japan)

^v BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; LIFICIGUAT; SHORT HAIRPIN RNA; TAMOXIFEN; UNCLASSIFIED DRUG; VAV PROTEIN; VAV3 PROTEIN; BIOLOGICAL MARKER; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; MEMBRANE PROTEIN; PROTEIN VAV3; RAC1 PROTEIN; 3-(5'-HYDROXYMETHYL-2'-FURYL)-1-BENZYLINDAZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ENZYME ACTIVATOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN; EXEMESTANE; INDAZOLE DERIVATIVE; LETROZOLE; NITRILE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SMALL INTERFERING RNA; TOREMIFENE; TRIAZOLE DERIVATIVE; TUMOR MARKER; VAV3 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; DISTANT METASTASIS FREE SURVIVAL; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR DOCKING; PROTEIN DEPLETION; PROTEIN MICROARRAY; QUANTITATIVE TRAIT LOCUS; WESTERN BLOTTING; ALLELE; BINDING AFFINITY; CANCER ADJUVANT THERAPY; CELL FRACTIONATION; DRUG PROTEIN BINDING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE IDENTIFICATION; GENE MUTATION; HUMAN TISSUE; MICROARRAY ANALYSIS; MONOTHERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATORS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; INDAZOLES; MCF-7 CELLS; NITRILES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-VAV; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAMOXIFEN; TOREMIFENE; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84903544283     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3664     Document Type: Article

References (64)

1. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
2. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008, 14:8019-8026.
3. Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007, 106:102-110.
4. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013, 45:1446-1451.
5. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013, 4:1116-1130.
6. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013, 45:1439-1445.
7. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
8. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011, 43:27-33.
9. Dunbier AK, Martin LA, Dowsett M. New and translational perspectives of oestrogen deprivation in breast cancer. Mol Cell Endocrinol 2011, 340:137-141.
10. Sabnis G, Brodie A. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clin Breast Cancer 2010, 10:E6-E15.
11. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987, 47:4355-4360.
12. Welshons WV, Jordan VC. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 1987, 23:1935-1939.
13. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998, 139:4164-4174.
14. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002, 81:333-341.
15. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer 2006, 13:827-837.
16. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008, 68:4910-4918.
17. Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010, 29:6071-6083.
18. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
19. Tolopko AN, Sullivan JP, Erickson SD, Wrobel D, Chiang SL, Rudnicki K, Rudnicki S, Nale J, Selfors LM, Greenhouse D, Muhlich JL, Shamu CE. Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities. BMC Bioinformatics 2010, 11:260.
20. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J. TM4 microarray software suite. Methods Enzymol 2006, 411:134-193.
21. Roy U, Luck LA. Molecular modeling of estrogen receptor using molecular operating environment. Biochem Mol Biol Educ 2007, 35:238-243.
22. Morley SD, Afshar M. Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock. J Comput Aided Mol Des 2004, 18:189-208.
23. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, Smith CL, Afonine PV, Adams PD, Katzenellenbogen JA, Nettles KW. Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol 2010, 6:837-843.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
25. van de Vijver MJ, He YD, van' t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
26. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008, 9:R137.
27. Zhu LJ, Gazin C, Lawson ND, Pagès H, Lin SM, Lapointe DS, Green MR. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics 2010, 11:237.
28. Strutt H, Paro R. Mapping DNA target sites of chromatin proteins in vivo by formaldehyde crosslinking. Methods Mol Biol 1999, 119:455-467.
29. Vicent GP, Nacht AS, Font-Mateu J, Castellano G, Gaveglia L, Ballaré C, Beato M. Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev 2011, 25:845-862.
30. Citterio C, Menacho-Márquez M, García-Escudero R, Larive RM, Barreiro O, Sánchez-Madrid F, Paramio JM, Bustelo XR. The Rho exchange factors Vav2 and Vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal 2012, 5:ra71.
31. López-Lago M, Lee H, Cruz C, Movilla N, Bustelo XR. Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol Cell Biol 2000, 20:1678-1691.
32. Rutqvist LE, Johansson H, . on behalf of the Stockholm Breast Cancer Study Group Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007, 46:133-145. on behalf of the Stockholm Breast Cancer Study Group.
33. Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997, 57:3486-3493.
34. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985, 117:1409-1417.
35. Fallahian F, Karami-Tehrani F, Salami S, Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J 2011, 278:3360-3369.
36. Bellis LJ, Akhtar R, Al-Lazikani B, Atkinson F, Bento AP, Chambers J, Davies M, Gaulton A, Hersey A, Ikeda K, Krüger FA, Light Y, McGlinchey S, Santos R, Stauch B, Overington JP. Collation and data-mining of literature bioactivity data for drug discovery. Biochem Soc Trans 2011, 39:1365-1370.
37. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007, 35:D198-D201.
38. Steffan RJ, Matelan E, Ashwell MA, Moore WJ, Solvibile WR, Trybulski E, Chadwick CC, Chippari S, Kenney T, Eckert A, Borges-Marcucci L, Keith JC, Xu Z, Mosyak L, Harnish DC. Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J Med Chem 2004, 47:6435-6438.
39. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC. Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci U S A 2005, 102:2543-2548.
40. Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 2011, 18:C19-C24.
41. Fujikawa K, Inoue Y, Sakai M, Koyama Y, Nishi S, Funada R, Alt FW, Swat W. Vav3 is regulated during the cell cycle and effects cell division. Proc Natl Acad Sci U S A 2002, 99:4313-4318.
42. Wu F, Peacock SO, Rao S, Lemmon SK, Burnstein KL. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. J Biol Chem 2013, 288:5463-5474.
43. Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M, Tanigawara Y, Imamura CK, Flockhart DA, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet 2012, 21:1665-1672.
44. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, Maouche S, Germain M, Lackner K, Rossmann H, Eleftheriadis M, Sinning CR, Schnabel RB, Lubos E, Mennerich D, Rust W, Perret C, Proust C, Nicaud V, Loscalzo J, Hübner N, Tregouet D, Münzel T, Ziegler A, Tiret L, Blankenberg S, Cambien F. Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PLoS One 2010, 5:e10693.
45. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
46. Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 2012, 31:716-727.
47. Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjöld B, Hallbeck AL, Stål O. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res 2013, 15:R96.
48. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B, Stål O. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013, 137:397-406.
49. Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O. Estrogen receptor-α phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010, 16:1624-1633.
50. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
51. Manetz TS, Gonzalez-Espinosa C, Arudchandran R, Xirasagar S, Tybulewicz V, Rivera J. Vav1 regulates phospholipase Cγ activation and calcium responses in mast cells. Mol Cell Biol 2001, 21:3763-3774.
52. Houlard M, Arudchandran R, Regnier-Ricard F, Germani A, Gisselbrecht S, Blank U, Rivera J, Varin-Blank N. Vav1 is a component of transcriptionally active complexes. J Exp Med 2002, 195:1115-1127.
53. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003, 9:524S-532S.
54. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, Welsh J, Wang LH. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 2000, 20:9212-9224.
55. Lee K, Liu Y, Mo JQ, Zhang J, Dong Z, Lu S. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 2008, 8:158.
56. Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr Relat Cancer 2011, 18:207-219.
57. Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, Wang LH. Vav3-Rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res 2012, 72:3000-3009.
58. Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res 2011, 13:R29.
59. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010, 126:545-562.
60. Sutherland RL. Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. Breast Cancer Res 2011, 13:106.
61. Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012, 72:5048-5059.
62. Peacock SO, Fahrenholtz CD, Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol 2012, 26:1967-1979.
63. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 1994, 29:117-125.
64. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A, Cinieri S. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?. Crit Rev Oncol Hematol 2012, 84:243-251.